LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES

被引：1
|
作者：
Tachdjian, R.
Anderson, J.
Busse, P.
Johnston, D.
Kiani, S.
Nurse, C.
Paes, K.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2018年 / 121卷 / 05期
关键词：
D O I：
10.1016/j.anai.2018.09.119
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P171
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [21] LANADELUMAB SAFETY AND IMMUNOGENICITY: RESULTS FROM THE PHASE 3 HELP STUDY
    Johnston, D.
    Banerji, A.
    Riedl, M.
    Zuraw, B.
    Lumry, W.
    Bernstein, J.
    Li, H.
    Lu, P.
    Hao, J.
    Gower, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S36 - S36
  • [22] Interpreting efficacy outcomes from open-label extension studies of anti-epileptic drugs
    Maguire, Melissa J.
    Hemming, K.
    Hutton, J.
    Marson, A.
    EPILEPSIA, 2007, 48 : 312 - 312
  • [23] Results of switching to laquinimod in the open-label extension phase of the BRAVO study
    Vollmer, T.
    Sorensen, P. S.
    Selmaj, K.
    Zipp, F.
    Havrdova, E.
    Cohen, J.
    Sidi, Y.
    Gorfine, T.
    Arnold, D.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 489 - 489
  • [24] Results from an open-label extension study of etanercept in ankylosing spondylitis
    Davis, J
    Webb, A
    Lund, S
    Sack, K
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (02): : 302 - 304
  • [25] Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)
    Watt, Maureen
    Maurer, Marcus
    Devercelli, Giovanna
    Paes, Kim
    Regnault, Antoine
    Meunier, Julliette
    Bunod, Laurine
    Riedl, Marc
    Lumry, William
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB24 - AB24
  • [26] Long-term efficacy and safety of switching from adalimumab to risankizumab: results from the open label extension LIMMitless
    Reich, Kristian
    Ryan, Caitriona
    Crowley, Jeffrey
    Szepietowski, Jacek C.
    Zeng, Jiewei
    Valdes, Joaquin
    Photowala, Huzefa
    Kaufmann, Christian
    Gooderham, Melinda
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 19 - 20
  • [27] Switching double-blind opicapone, entacapone or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I
    Ferreira, J.
    Lees, A.
    Tolosa, E.
    Poewe, W.
    Santos, A.
    Lopes, N.
    Rocha, J. F.
    Soares-da-Silva, P.
    MOVEMENT DISORDERS, 2016, 31 : S633 - S633
  • [28] ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY
    Cohen, S.
    Pablos, J. L.
    Wang, H.
    Mueller, G. A.
    Kivitz, A.
    Matsumoto, A.
    Krishnan, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 834 - 835
  • [29] DONIDALORSEN FOR HEREDITARY ANGIOEDEMA: RESULTS FROM THE OASISPLUS OPEN-LABEL EXTENSION STUDY
    Tachdjian, R.
    Riedl, M.
    Bordone, L.
    Newman, K.
    Treadwell, S.
    Lin, T.
    Yarlas, A.
    Cohn, D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S38 - S38
  • [30] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345